INTRODUCTION
Cancer chemotherapy is challenged with the problem of delivering the required therapeutic concentration of the drug at the tumor site for the desired period of time without causing undesirable effects on other organs after systemic ad ministration.
1,2, 3 Targeted delivery of anticancer drugs to solid tumors, therefo re, is necessary in order to achieve optimu m therapeutic outcomes. Nanoscale devices has led to the development of biodegradable selfassembled nanoparticles, which are being engineered for the targeted delivery of anticancer drugs and imag ing contrast agents capable of ferry ing large doses of chemotherapeutic agents into malignant cells sparing the healthy cells.
Tamo xifen citrate, the nonsteroidal antiestrogen is the treatment of choice for patients with all stages of estrogen receptor positive breast cancer.
4, 5 Tamo xifen belongs to a class of nonsteroidal triphenylethylene derivatives and is considered the first selective estrogen receptor modulator.
6, 7 The drug exhibits anti-estrogenic activity by binding to the intracellular estrogen receptor. 8 The Tamo xifen-estrogen receptor complex binds with DNA and can alter or block subsequent mRNA transcription and lead to cellular apoptosis.
9,10
Tamo xifen has some majo r side effects following longterm therapy in postmenopausal breast cancer patients, including higher incidence of endometrial cancer, liver cancer, thromboembo lic disorders, and development of drug resistance.
11 Tamo xifen resistance has been shown in a variety of cells in vitro as well as in vivo.
12 These unwanted side effects of Tamo xifen, as well as various barriers to the delivery of the drugs to tumor, call for targeted delivery to the tumor site and enhanced uptake by the tumor cells. One approach to overcome the undesirable side effects of Tamo xifen includes the use of biodegradable polymeric nanoparticles for tumo r-targeted drug delivery. Tamo xifen has been formulated in nanoparticulate carrier systems in the form of nanospheres such as poly-ε-caprolactone nanoparticles and longcirculat ing PEG-coated poly(MePEG cyanoacrylatecohexadecylcyanoacrylate) nanoparticles in the form of free base.
13, 14 It is known that the tumor vasculature is leaky and possesses an enhanced capacity for the uptake of macro molecules and colloidal drug carriers of up to 400 nm in diameter. Th is effect is known as the enhanced permeab ility and retention (EPR) effect.
15,16,17 Thus, such a delivery method could improve the selectivity of treatment by increasing the ratio of tamo xifen absorbed by the tumor
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to tamoxifen absorbed by other tissues, leading to a reduction in the systemic side effects.
On the other hand, the coating with polymers provides sustained release along with protection of the active drug fro m gastric fluid.
18, 19 Polysaccharides, the polymers of monosaccharides, retain their integrity in the upper gastrointestinal tract because they are resistant to the digestive action of gastrointestinal enzymes. The polysaccharide, guar gum, obtained from the seeds o f Cyamposis tetragonolobus, is a low cost, easily available, non toxic, biodegradable poly mer. It consists of linear chains of (1→4)β-D-manopyranosy1 units with β-Dgalactopyranosy1 units attached by (1→6) linkages. 20 Guar gum is hydrophilic in nature and swells in cold water forming viscous colloidal dispersions or sols. This gelling property retards release of the drug from the dosage form which makes it an ideal carrier in drug delivery.
20, 21, 22, 23
We have reported earlier about the formulat ion development aspects of crosslinked guar gum nanoparticles containing tamo xifen citrate and characterized the nanoparticles for morphology, drugpolymer interaction, drug loading efficiency and drug release for finding its applicat ions in drug delivery to cancer.
24, 25 In the present investigation, we have studied the internal morphology and shape of nanoparticles in TEM and anticancer efficacy of the drug loaded guar gum nanoparticles on Jurkat (hu man T-cell leukemia) cell line. Citrate salt was preferred to Tamo xifen free base due to its higher efficacy and the fact that commercially marketed products are manufactured with Tamo xifen citrate.
MATERIALS AND METHODS

Materials
Central Drugs Laboratory, Kolkata, India generously supplied tamo xifen citrate as gift samp le. Guar gu m was purchased from Central Drug House, New Delh i, India. Span 80, and glycerol were procured fro m M/S Ranbaxy Ltd. Glutaraldehyde (25% aqueous solution) was procured fro m Sig ma Chemicals, USA. All other solvents were of HPLC grade. Jurkat (hu man T-cell leukemia) cell line was obtained from National Centre for Cell Science (NCCS), Pune, India. WST-1(Cell pro liferation reagent) were purchased from Roche Diagnostics, Mannheim, Germany and RPMI 1640 (Roswell Park Memorial Institute mediu m 1640), Fetal Bov ine Seru m, penicillin -G, Strepto mycin, Gentamycin were procured fro m Invitrogen, Carlsbad, CA.
Preparation of nanoparticles
Guar gu m nanoparticles containing tamo xifen citrate were prepared by oil in water emu lsion in-situ polymer crosslinking technique. 24 Briefly 5mg of the drug tamo xifen citrate was taken in 10ml of d ichloro methane (DCM), this formed the oil phase. To this added 4 mg of Span 80 under stirring. The oil phase was then added to a 0.5% aqueous guar gum solution under constant magnetic stirring. After mutual saturation of the oil and the continuous phase, the mixtu re was rapidly stirred. Glycerol (as stabilizer) was then added followed by addition of 25% glutaraldehyde solution to affect crosslinking under continuous stirring. Nanosuspension was kept overnight for nanoparticle formation. Nanoparticles were obtained after centrifugation at 20,000 rp m for 30minutes, washed with 15 ml HPLC grade water and recentrifuged. The yielded nanoparticles were lyophilized, harvested in micro centrifuge tubes and preserved in vacuum desiccators.
CHARACTERIZATION OF TAMOXIFEN CITRATE LOADED GUAR GUM NANOPARTICLES
Size distribution in TEM
Transmission electron microscopy (FEI Technai 12 BioTwin, The Netherlands) with a CCD camera mega view II soft imag ing system was emp loyed to visualize and record the nature and the size distribution of NPs. A generalized protocol was used for TEM studies. 26 A drop of water suspension of the GG NPs was mounted on a carbon coated copper grid (CCG) and air-dried and micro graphed at 80-100kV ( fig. 1) .
In vitro cytotoxicity analysis of free tamoxifen citrate and tamoxifen citrate loaded g uar gum nanoparticles on J urkat (human T-cell leukemia) cell lines Jurkat (human T-cell leukemia) cells (Nat ional Centre for Cell Science (NCCS), Pune, India) were cu ltured in RPMI 1640(Roswell Park Memorial Institute mediu m 1640) was used at pH 7.4, supplemented with 10% Fetal Bovine Seru m and antibiotics (100U/ ml penicillin -G, 100μg/ mlsterptomycin, 6μg/ ml Gentamycin ). The cells were incubated at 37 0 C in a hu midified at mosphere containing 5% CO 2 inside a CO 2 incubator.
WST-1 assay:
The antiproliferative assay was carried out using the commercially available colorimetric assay kit WST-1 (Cell proliferation reagent, Roche, Germany). The cells (5 X10 4 cells in 100 µl mediu m/well) were plated in 0.05% DMSO in media as control in 96-well plates. The cells as such or in the presence of varying concentration of free tamo xifen citrate and loaded NPs (dissolved in 0.5% DMSO in medi a) were incubated for 48 h. At the end of the treatments, each well was treated with WST-1 solution (10 µl), and after incubation for 2 h, the absorption at 450 n m was read with a microplate reader (BIOTEK; ELX 800, USA). The inhibition of cell pro liferation by TMX and TMX loaded GG NPs was evaluated by calculating the IC 50 values.
Where A control , A treated are the absorbances of control and free TM X and TMX loaded GG NPs.
RES ULTS AND DISCUSS ION
In the present study tamo xifen citrate loaded guar gum nanoparticles in the size range of 200-300n m were prepared via a oil in water emu lsion insitu polymer crosslinking technique. Transmission electron microscopy analysis of drug loaded NPs were spherical with a dense TMX core (Fig. 1) . Average TEM diameter was observed to be 205 n m. The antiproliferative action of free tamo xifen cit rate and tamo xifen citrate loaded guar gum nanoparticles was investigated on Jurkat (human T-cell leukemia) cell line. For this purpose pure drug and drug loaded nanoparticles were applied on the cancer cells in-vitro against a control experiment with cancer cells in the culture media without the free drug and nanoparticles. The microscopic images of control cells without any drug exposure and cells incubated with empty guar gum nanoparticles did not show any cell death, where as the images of cells treated with encapsulated and free tamo xifen citrate exh ib ited cell death (Figure 3a -3b ) . A dose dependent cytotoxicity was observed with TMX and TMX loaded GG NPs (table1 and figure 2 ). The cell morphology was observed and no loss in cellu lar morphology was found when cells were treated with empty GG NPs but significant changes were found after treat ment with free TM X and TMX loaded guar gum nanocarriers. Loss of aggregation and lysis of cells were observed under these conditions as presented in figure 3a-3b.
Since, guar gum is nontoxic and is approved by FDA for pharmaceutical applicat ions, it is expected that the drug loaded guar gum nanoparticles should be biocompatible, biodegradable and potentially safe as a drug carrier for clin ical use. In vitro cytotoxicity assay proved that empty nanocarriers showed no cytotoxicity and TMX loaded nanoparticles was as effective as free TMX. It is observed that there is significant change in morphology of the cells after treatment with TMX and TMX loaded nanoparticles suggesting effectiveness of TMX loaded guar gum nanoparticles on the experimental cell line and eliminating the probability of plain guar gum induced cytological changes in the present investigation. It is evident from table1 and figure 2 that the trend of % cell death tends to decrease at nanoparticle dose of 50 μM and more. One possible explanation for this fact may be a progressive saturation of the endocytotic process with time suggesting a saturable kinetics for the transport of nanoparticles. 27 The cellular uptake of guar gu m nanoparticles may be assumed to be med iated by non specific endocytotic process rather than receptor mediated. Similar results were observed by Amiji et al. 28 The inhibitory IC50 for both free TMX and TMX loaded GG NPs was found to be below 25μM. Based on the saturation of the endocytotic process for the nanoparticles, it may be assumed that at higher doses of nanoparticles (50μM and more) the intercellular Tamo xifen concentration was not as high as it should be resulting in the reduced rate of cell death of the cells. The cellu lar uptake o f free drug however can occur either by passive diffusion and pinocytosis., 29 
Pinocytosis
main ly performs the capture of macro molecules adherent to the surface membrane. The size of an average pinocytic vesicle is about 100 to 200 nm. 30 It may further be assumed that the free drug solution will be distributed all over the body whereas the NPs (200-300n m) may be preferentially distributed in the tu mor tissue because of the EPR effect. Leaky vasculature and lack of effect ive ly mphatic drainage fro m the tumour results in the extravasation and accumulation of particulates, plasma proteins and other macro mo lecules.
31
This trapping of macro molecu les has been termed the "enhanced permeability and retention" (EPR).
32,33 EPR effect is now thought to contribute to the effects of many anticancer drugs delivered as conjugates with synthetic polymers 34,35 or in liposomes.
highly protein bound drugs (anthracylcines, paclitaxel, etoposide) also seems to be mediated through the EPR.
37
However, the cut-off size of the permeable vasculature varies fro m tu mour to tumour, and the size of a drug carrying particle may be used to control the passive drug delivery. 38 Do xorubicin incorporated into long circulating pegylated liposomes showed excellent tumour accumulat ion through EPR and reduced side effects of doxorubicin.
39,40
With the support of the established literature we may assume that the prepared guar gum nanoparticles of 200-300n m size are preferentially accumulated on the Jurkat cells by EPR effect and is expected to increase the concentration of drug inside the tumor cells as a result of a nonspecific endocytotic process, followed by a gradual release of the drug and binding of tamo xifen to the estrogen receptor around the nucleus to produce the desired antitumor effect. Under these conditions the formulations of predesigned nanoparticles with calculated process parameter may be very efficient tool for intercellular delivery of anticancer drugs like tamo xifen cit rate. These results demonstrated that this delivery system could be a promising choice for administering tamo xifen citrate without loss of its therapeutic efficacy.
CONCLUS ION
Nanoparticles by virtue of its size and properties are potential tools for treating cancer. Guar gu m nanoparticles containing tamoxifen citrate under the present investigation exhibited the benefits of nanoencapsulation for highly p rotein binding drug tamo xifen citrate in passive targeting of cancer. The drug loaded nanoparticles were as efficient as the free drug when applied to the cancer cells.
However, the crosslinked guar gum nanoparticles loaded with tamo xifen cit rate exhib ited sustained release of the drug and delayed apoptosis over a long period of time making it suitable for cancer treat ment.
